Adagene Starts Global Trial of CTLA-4 Inhibitor for Solid Tumor Cancers
publication date: Mar 16, 2021
Adagene, a Suzhou-San Francisco immunotherapy company, has begun dosing patients in a global Phase I trial of ADG126 in patients with advanced solid tumors. ADG126, Adagene’s lead SAFEbody™ product candidate, is a fully-human, antagonistic mAb targeting a novel epitope of CTLA-4. The company said its SAFEbody platform is designed to limit the safety issues of anti-CTLA-4 therapies by limiting on-target off-tumor toxicities in normal tissues. Adagene developed SAFEbody using its AI-powered platform. More details...
Stock Symbol: (NSDQ: ADAG)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.